1728P Initial experience with 177Lu-DOTATATE in patients with neuroendocrine neoplasms: A multicenter retrospective study in Japan
Hiroshi Imaoka(National Cancer Center Hospital East), J. Furuse(Kanagawa Prefectural Hospital Organization), Nao Fujimori(Kyushu University), Hiroomi Okuyama(The University of Osaka), Takahiro Ono(Osaka Dental University), Ryoji Takada(Osaka International Cancer Institute), Ichiro Yokota(Yale University), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Takeshi Terashima(Kobe University), Noritoshi Kobayashi, Kohji Hara(Niigata University), Kohei Okamoto(National Cancer Center Hospital East), C. Morizane(National Cancer Center Hospital East), Shigeru Horiguchi(Okayama University), Kazuhiko Shioji(Niigata Cancer Center Hospital), S. Kondo(Tokyo Women's Medical University), Kenichi Sudo(Chiba Cancer Center), Satoshi Shimizu(Saitama Cancer Center), S. Takeuchi(Sapporo Medical University), Masato Ozaka(The Cancer Institute Hospital)
Cited by 0
Related Papers
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
|The Lancet. Gastroenterology & hepatology|2019|331
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
|Japanese Journal of Clinical Oncology|2017|274